Personal Human lmmune System Mice: Accelerating the Translation of lmmuno-therapies from Bench to Bedside

Register Link:

https://www.eventbrite.com/e/genobiotx-february-2025-webinar-tickets-1228646116609?aff=oddtdtcreator

Date:

  • Wednesday, Feb. 26th, 2025; 2:00 pm EST or 11:00 am PST

Meet Our Speaker:

Dr. Huang earned a Ph.D. in 2004 from the Institute of Zoology, Chinese Academy of Sciences, followed by a postdoctoral fellowship at Peking University Health Science Center (2004–2006). Dr. Huang has dedicated over 15 years to groundbreaking research in the United States at prestigious institutions, including Albert Einstein College of Medicine, the Aaron Diamond AIDS Research Center, Rockefeller University, and Columbia University. A member of Sigma Xi, the Genetics Society of America, and the American Geriatrics Society, Dr. Huang has authored more than 30 peer-reviewed papers in esteemed journals such as Science Translational Medicine and Frontiers in Immunology. Their research focuses on tumor immunology, vaccines, infectious diseases, and animal model development. In 2019, Dr. Huang] founded Genomab Biotech (www.genomab.com) in New York, where they serve as CEO. In 2021, they further expanded their vision by establishing NexVivo Biotech in Suzhou, China, advancing innovation in the biotech industry globally.

About GenoBioTX

GenoBioTX provides comprehensive animal modeling services, ranging from model construction to preclinical in vitro and in vivo assays, based on the combination of versatile technical platforms and experienced scientist.

Contact us

Website: www.genobiotx.com
Email: info@genobiotx.com
Address: 10410 Corporate Dr., Sugar Land, TX, 77478, USA

Watch Video

    News Center

    2025.03.10

    Special Promotion: Humanized Models for Oncology Research (March–June)

    Accelerate your oncology research with GenoBioTX's humanized animal models. From March 1st to June 30th, we are offering a special promotion to support groundbreaking advancements in cancer research. Disease-Specific Humanized Models GenoBioTX provides a diverse range of humanized models tailored for high translational relevance across multiple disease areas, including: Oncology & Immuno-Oncology (Promotion Available) Tumor […]

    2024.11.01

    Why IL-2 Still Holds Promise in Therapeutics of Cancer and Autoimmunity

    Aclidineleukin (high-dose IL-2) is the first FDA-approved cancer immunotherapy for metastatic renal cell carcinoma (RCC) and melanoma, but the widespread clinical use of aclidinein has been limited by its short half-life, serious side effects, and simultaneous stimulation of Treg activation. With the breakthrough of studies of immune checkpoint inhibitors, IL-2-based therapeutics has regained widespread attention, […]

    Email Back to top